Expression of Ki67, BCL-2, and COX-2 in Canine Cutaneous Mast Cell Tumors: Association With Grading and Prognosis

Veterinary Pathology

Volumn 50, Issue 1, 2013, Pages 110-121

  Vascellari, M ^a   Giantin, M ^b   Capello, K ^a   Carminato, A ^a   Morello, E M ^c   Vercelli, A ^d   Granato, A ^a   Buracco, P ^c   Dacasto, M ^b   Mutinelli, F ^a  

^a ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Ambulatorio Veterinario Associato   (Italy)

Author keywords

BCL 2; COX 2; dog; immunohistochemistry; Ki67; mast cell tumors; prognosis; qPCR

Indexed keywords

CANIS FAMILIARIS;

CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN BCL 2; TUMOR MARKER;

ANIMAL; CANCER GRADING; DOG; DOG DISEASE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; METABOLISM; MITOSIS INDEX; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SARCOMA; SKIN; SKIN TUMOR; URTICARIA PIGMENTOSA; VETERINARY;

ANIMALS; CYCLOOXYGENASE 2; DOG DISEASES; DOGS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MAST CELLS; MAST-CELL SARCOMA; MASTOCYTOSIS, CUTANEOUS; MITOTIC INDEX; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872866559     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985812447829     Document Type: Article

References (80)

1. Abadie JJ,Amardeilh MA,Delverdier ME.Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.J Am Vet Med Assoc. 1999;215:1629-1634.
2. Aresu L,Giantin M,Morello M,et al.Matrix metalloproteinases and their inhibitors in canine mammary tumors.BMC Vet Res. 2011;7:33.
3. Baghestanian M,Jordan JH,Kiener HP,et al.Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2.Int Arch Allergy Immunol. 2002;129:228-236.
4. Baliga BC,Kumar S.Role of bcl-2 family of proteins in malignancy.Hematol Oncol. 2002;20:63-74.
5. Bostock DE.The prognosis following surgical removal of mastocytomas in dogs.J Small Anim Pract. 1973;14:27-41.
6. Bostock DE,Crocker J,Harris K,et al.Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours.Br J Cancer. 1989;59:915-918.
7. Brown MB,Forsythe AB.Robust test for the equality of variances.J Am Stat Ass. 1974;69:364-367.
8. Bullock ED,Johnson EM.Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells-potential role in survival promotion.J Biol Chem. 1996;271:27500-27508.
9. Cervero C,Escribano L,San Miguel JF,et al.Expression of bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia.Am J Hematol. 1999;60:191-195.
10. Costa C,Soares R,Reis-Filho JS,et al.Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.J Clin Pathol. 2002;55:429-434.
11. Dore M,Lanthier I,Sirois J.Cyclooxygenase-2 expression in canine mammary tumors.Vet Pathol. 2003;40:207-212.
12. Ebrahimi M,Roudkenar MH,Imani Fooladi AA,et al.Discrepancy between mRNA and protein expression of neutrophil gelatinase-associated lipocalin in bronchial epithelium induced by sulfur mustard.J Biomed Biotechnol. 2010;2010:823131.
13. Edwards JG,Faux SP,Plummer SM,et al.Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.Clin Cancer Res. 2002;8:1857-1862.
14. Elston LB,Sueiro FA,Cavalcanti JN,et al.The importance of the mitotic index as a prognostic factor for survival of canine cutaneous mast cell tumors: a validation study.Vet Pathol. 2009;46:362-364.
15. Findley HW,Gu L,Yeager AM,et al.Expression and regulation of bcl-2, bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.Blood. 1997;8:2986-2993.
16. Fosslien E.Molecular pathology of cyclooxygenase-2 in neoplasia.Ann Clin Lab Sci. 2000;30:3-21.
17. Fosslien E.Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.Ann Clin Lab Sci. 2001;31:325-348.
18. Gerdes J,Lemke H,Baisch H,et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.J Immunol. 1984;133:1710-1715.
19. Giles FJ,Kantarjian HM,Bekele BN,et al.Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.Br J Haematol. 2002;119:38-45.
20. Gottschalk AR,Boise LH,Thompson CB,et al.Identification of immunosuppressant-induced apoptosis in a murine B- cell line and its prevention by bcl-x but not bcl-2.Proc Natl Acad Sci USA. 1994;91:7350-7354.
21. Harris RE,Alshafie GA,Abou-Issa H,et al.Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor.Cancer Res. 2000;60:2101-2103.
22. Harris RE,Kasbari S,Farrar WB.Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.Oncol Rep. 1999;6:71-73.
23. Hartmann K,Artuc M,Baldus SE,et al.Expression of Bcl-2 and Bcl-XL in cutaneous and bone marrow lesions of mastocytosis.Am J Pathol. 2003;163:819-826.
24. Heller DA,Clifford CA,Goldschmidt MH,et al.Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor.Vet Pathol. 2005;42:350-353.
25. Hinz B,Brune K.Cyclooxygenase-2-10 years later.J Pharmacol Exp Ther. 2002;300:367-375.
26. Hottendorf GH,Nielsen SW.Pathologic survey of 300 extirpated canine mastocytomas.Zbl Vet Med A. 1967;14:272-281.
27. Hueber AO,Raposo G,Pierres M,et al.Thy-1 triggers mouse thymocyte apoptosis through a bcl-2-resistant mechanism.J Exp Med. 1994;179:785-796.
28. Khan KN,Knapp DW,Denicola DB,et al.Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs.Am J Vet Res. 2000;61:478-481.
29. Khan KN,Stanfield KM,Trajkovic D,et al.Expression of cyclooxygenase-2 in canine renal cell carcinoma.Vet Pathol. 2001;38:116-119.
30. Kim YB,Kim GE,Cho NH,et al.Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.Cancer. 2002;95:531-539.
31. Kitada S,Andersen J,Akar S,et al.Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses.Blood. 1998;9:3379-3389.
32. Kitada S,Pedersen IM,Schimmer AD,et al.Dysregulation of apoptosis genes in hematopoietic malignancies.Oncogene. 2002;13:3459-3474.
33. Kiupel M,Webster JD,Bailey KL,et al.Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior.Vet Pathol. 2011;48:147-155.
34. Kluck RM,Bossy-Wetzel E,Green DR,et al.The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis.Science. 1997;275:1132-1136.
35. Knapp DW,Richardson RC,Chan TC,et al.Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.J Vet Intern Med. 1994;8:273-278.
36. Korsmeyer SJ.Bcl-2: a repressor of lymphocyte death.Immunol Today. 1992;13:285-288.
37. Lavalle GE,Bertagnolli AC,Tavares WL,et al.Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival.Vet Pathol. 2009;46:1275-1280.
38. Livak KJ,Schimittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method.Methods. 2001;25:402-408.
39. Maglennon GA,Murphy S,Adams V,et al.Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.Vet Comp Oncol. 2008;6:268-274.
40. Maiolino P,Cataldi M,Paciello O,et al.Nucleomorphometric analysis of canine cutaneous mast cell tumours.J Comp Pathol. 2005;133:209-211.
41. McEntee MF,Cates JM,Neilsen N.Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs.Vet Pathol. 2002;39:428-436.
42. Mekori YA,Gilfillan AM,Akin C,et al.Human mast cell apoptosis is regulated through bcl-2 and bcl-xL.J Clin Immunol. 2001;21:171-174.
43. Millanta F,Citi S,Della Santa D,et al.COX-2 expression in canine and feline invasive mammary carcinomas: correlations with clinicopathological features and prognostic molecular markers.Breast Cancer Res. 2006;98:115-120.
44. Mukaratirwa S.Prognostic and predictive markers in canine tumours: rationale and relevance.A review. Vet Q. 2005;27:52-64.
45. Mullins MN,Lana SE,Dernell WS,et al.Cyclooxygenase-2 expression in canine appendicular osteosarcoma.J Vet Intern Med. 2004;18:859-865.
46. Murphy S,Sparkes AH,Smith KC,et al.Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection.Vet Rec. 2004;154:743-746.
47. Northrup NC,Harmon BG,Gieger TL,et al.Variation among pathologists in histologic grading of canine cutaneous mast cell tumors.J Vet Diagn Invest. 2005;17:245-248.
48. Northrup NC,Howerth EW,Harmon BG,et al.Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference.J Vet Diagn Invest. 2005;17:561-564.
49. O'Keefe DA.Canine mast cell tumors.Vet Clin N Am Small Anim Pract. 1990;20:1105-1115.
50. Patnaik AK,Ehler WJ,MacEwen EG.Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs.Vet Pathol. 1984;21:469-474.
51. Pestili de Almeida EM,Piche C,Sirois J,et al.Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs.J Histochem Cytochem. 2001;49:867-875.
52. Preziosi R,Sarli G,Paltrinieri M.Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours.Vet Res Comm. 2007;31:287-296.
53. Queiroga FL,Alves A,Pires I,et al.Expression of Cox-1 and Cox-2 in canine mammary tumours.J Comp Pathol. 2007;136:177-185.
54. Queiroga FL,Perez-Alenza MD,Silvan G,et al.Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.Anticancer Res. 2005;25:4269-4275.
55. Rasmussen R.Quantification on the light cycler In: Meuer SC Wittwer C Nakagawara K, eds.Rapid Cycle Real-Time PCR: Methods and Applications Heidelberg Germany: Springer. 2001;21:.
56. Reddy ST,Wadleigh DJ,Herschman HR.Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells.J Biol Chem. 2000;275:3107-3113.
57. Romansik EM,Reilly CM,Kass PH,et al.Mitotic index is predictive for survival for canine cutaneous mast cell tumors.Vet Pathol. 2007;44:335-341.
58. Ruvolo PP,Deng X,May WS.Phosphorylation of Bcl2 and regulation of apoptosis.Leukemia. 2001;15:515-522.
59. Sakai H,Noda A,Shirai N,et al.Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression.J Comp Pathol. 2002;127:233-238.
60. Salomons GS,Smets LA,Verwijs-Janssen M,et al.Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.Leukemia. 1999;13:1574-1580.
61. Scase TJ,Edwards D,Miller J,et al.Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis.J Vet Int Med. 2006;20:151-158.
62. Schmidt BR,Glickman NW,DeNicola DB,et al.Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs.J Am Vet Med Assoc. 2001;218:1783-1786.
63. Scholzen T,Gerdes J.The Ki-67 protein: from the known and the unknown.J Cell Physiol. 2000;182:311-322.
64. Séguin B,Leibman NF,Bregazzi VS,et al.Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999).J Am Vet Med Assoc. 2001;218:1120-1123.
65. Simoes JP,Schoning P,Butine M.Prognosis of canine mast cell tumors: a comparison of three methods.Vet Pathol. 1994;31:637-647.
66. Taketo MM.Cyclooxygenase-2 inhibitors in tumorigenesis (part I).J Natl Cancer Inst. 1998;90:1529-1536.
67. Thamm DH,Vail DM.,Mast cell tumors.In: Withrow SJ, MacEwen EG, eds.Withrow and MacEwen's Small Animal Clinical Oncology 4th ed. St. Louis MI: Saunders- Elsevier. 2007;:402-424.
68. Tu Y,Renner S,Xu F,et al.Bcl-x expression in multiple myeloma: possible indicator of chemoresistance.Cancer Res. 1998;58:256-262.
69. Wang G,Lai FM,Lai KB,et al.Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy.Am J Nephrol. 2009;29:524-531.
70. Webster JD,Yuzbasiyan-Gurkan V,Miller RA,et al.Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.Vet Pathol. 2007;44:298-308.
71. Weisse C,Shofer FS,Sorenmo K.Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision.J Am Anim Hosp Assoc. 2002;38:71-73.
72. Welle MM,Rohrer Bley C,Howard J,et al.Canine mast cell tumour: a review of the pathogenesis, clinical features, pathology and treatment.Vet Dermatol. 2008;19:321-339.
73. Williams CS,Mann M,DuBois RN.The role of cyclooxygenases in inflammation, cancer and development.Oncogene. 1999;18:7908-7916.
74. Willimott S,Wagner SD.Post-transcriptional and post-translational regulation of BCL-2.Biochem Soc Trans. 2010;38:1571-1575.
75. Xerri L,Hassoun J,Devilard E,et al.Bcl-x and the apoptotic machinery of lymphoma cells.Leuk Lymphoma. 1998;28:451-458.
76. Xiang Z,Ahmed AA,Moeller C,et al.Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation.J Exp Med. 2001;194:1561-1569.
77. Xu XC.COX-2 inhibitors in cancer treatment and prevention, a recent development.Anticancer Drugs. 2002;13:127-137.
78. Yang E,Korsmeyer SJ.Molecular thanatopsis: a discourse on the BCL2 family and cell death.Blood. 1996;88:386-401.
79. Yeatman CF,Jacobs-Helber SM,Mirmonsef P,et al.Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis.J Exp Med. 2000;192:1093-1103.
80. Yee NS,Peak I,Besmer P.Role of c-kit ligand in proliferation and suppression of apoptosis in mast cells. Basis for radiosensitivity of white spotting and steel mutants.J Exp Med. 1994;179:1777-1787.